Search Results - José‐Ángel Hernández‐Rivas

Refine Results
  1. 1
    Leukemias, myeloma, and other lymphoreticular neoplasms

    Leukemias, myeloma, and other lymphoreticular neoplasms by José‐Ángel Hernández‐Rivas, Kevin J. Land, Robert W. McKenna

    Published 1995
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies

    The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies by José‐Ángel Hernández‐Rivas, Rafael Ríos, Cristina Encinas, Rafael Alonso, Juan José Lahuerta

    Published 2022
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings [see comments]

    Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings [see comments] by Antonio Cuneo, A Ferrant, Jl. Michaux, M. Boogaerts, H Demuynck, Angeline Van Orshoven, A. Criel, Michel Stul, Paola Dal Cin, José‐Ángel Hernández‐Rivas

    Published 1995
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

    Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis by Simon Rule, Martin Dreyling, André Goy, Georg Heß, Rebecca Auer, Brad S. Kahl, José‐Ángel Hernández‐Rivas, Keqin Qi, Sanjay Deshpande, Lori Parisi, Michael Wang

    Published 2018
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  5. 5
    Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up

    Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up by Martin Dreyling, André Goy, Georg Heß, Brad S. Kahl, José‐Ángel Hernández‐Rivas, Natasha Schuier, Keqin Qi, Sanjay Deshpande, Angeline Zhu, Lori Parisi, Michael Wang

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    High‐sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma

    High‐sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma by Júlia Almeida, Alberto Órfão, Mauricio Ocqueteau, Gema Mateo, Mercedes Corral, Ma Delores Caballero, Joan Bladé, Ma Jesus Moro, José‐Ángel Hernández‐Rivas, Jesús F. San Miguel

    Published 1999
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Association between different risk factors and vascular accelerated ageing (EVA study): study protocol for a cross-sectional, descriptive observational study

    Association between different risk factors and vascular accelerated ageing (EVA study): study protocol for a cross-sectional, descriptive observational study by Manuel A. Gómez‐Marcos, Carlos Martínez‐Salgado, Rogelio González‐Sarmiento, José‐Ángel Hernández‐Rivas, Pedro L. Sánchez, José I. Recio‐Rodriguez, Emiliano Rodríguez‐Sánchez, Luis García‐Ortiz

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome

    Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome by Jesús F. San Miguel, Júlia Almeida, Gema Mateo, Joan Bladé, C López-Berges, Dolores Caballero, José‐Ángel Hernández‐Rivas, Marı́a Jesús Moro, Javier Fernández‐Calvo, Joaquín Diaz‐Mediavilla, Luis Palomera, Alberto Órfão

    Published 2002
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Clinical outcome and prognostic factors of patients with Richter syndrome: real‐world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)

    Clinical outcome and prognostic factors of patients with Richter syndrome: real‐world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC) by Pau Abrisqueta, Julio Delgado, Miguel Alcoceba, Ana Carla Oliveira, Javier Loscertales, José‐Ángel Hernández‐Rivas, Christelle Ferrà, Raúl Córdoba, Lucrecia Yáñez, Ángeles Medina, Cristina Motlló, Gloria Iacoboni, Guillermo Villacampa, Marcos González, Francesc Bosch

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Chronic Lymphocytic Leukemia: A Paradigm of Innate Immune Cross-Tolerance

    Chronic Lymphocytic Leukemia: A Paradigm of Innate Immune Cross-Tolerance by Teresa Jurado-Camino, Raúl Córdoba, Laura Esteban-Burgos, Enrique Hernández-Jiménez, Víctor Toledano, José‐Ángel Hernández‐Rivas, Elena Ruiz-Sainz, Teresa Cobo, María Siliceo, Rebeca Pérez de Diego, Cristóbal Belda-Iniesta, Carolina Cubillos‐Zapata, Eduardo López‐Collazo

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Dose‐intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status

    Dose‐intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status by Josep‐María Ribera, Olga García, Carlos Grande, Jordi Esteve, Albert Oriol, Juan Bergua, José González‐Campos, Ferrán Vall-Llovera, Mar Tormo, Jesús María Hernández‐Rivas, Daniel Fernández-García, Salut Brunet, Natalia Alonso, Pere Barba, Pilar Miralles, Andreu Llorente, Pau Montesinos, M.-J. Moreno, José‐Ángel Hernández‐Rivas, Teresa Bernal

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

    Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy by José Cervera, Pau Montesinos, José‐Ángel Hernández‐Rivas, Marı́a José Calasanz, Ana Aventín, Maria Teresa Ferrò, Elisa Luño, Javier Sánchez, Edo Vellenga, Chelo Rayón, Giuseppe Milone, Javier de la Serna, Concepción Rivas, Juan D. González, Mar Tormo, Elena Amutio, Marcos González, Salut Brunet, Bob Löwenberg, Miguel Á. Sanz

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera

    Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera by Alberto Álvarez‐Larrán, Ana Kerguelen, Juan Carlos Hernández‐Boluda, Manuel Pérez‐Encinas, Francisca Ferrer‐Marín, Abelardo Bárez, Joaquín Martínez‐López, Beatriz Cuevas, María Isabel Mata, Valentín García‐Gutiérrez, P. Aragües, Sara Montesdeoca, Carmen Burgaleta, Gonzalo Caballero, José‐Ángel Hernández‐Rivas, Maria Antònia Durán, María Teresa Gómez‐Casares, Carles Besses

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia

    A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia by José‐Ángel Hernández‐Rivas, Alfredo E. Rodríguez, Marcos González, Rocí­o Benito, Celia Fontanillo, Virgilio Sandoval, Marta Romero-Gutiérrez, Guillermo Martín–Núñez, Alfonso García de Coca, Rosa Fisac, Josefina Galende, Isabel Recio, Francisco José Ortuño, Juan Luis Garcı́a, Javier De Las Rivas, Norma C. Gutiérrez, Jesús F. San Miguel, Jesús María Hernández‐Rivas

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

    First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study by Carol Moreno, Talha Munir, Carolyn Owen, George Follows, Jose-Angel Hernandez Rivas, Ohad Benjamini, Ann Janssens, Mark‐David Levin, Tadeusz Robak, Martin Šimkovič, Sergey Voloshin, Vladimir Vorobyev, Münci Yağcı, Loïc Ysebaert, Qianya Qi, Emma A. Elliott Smith, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P. Kater

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

    The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis by Bruno Paiva, María‐Belén Vidriales, Jose J. Pérez, María‐Consuelo López‐Berges, Ramón García‐Sánz, Enrique M. Ocio, Natalia de las Heras, Rebeca Cuello, Alfonso García de Coca, Emilia Pardal, José María Alonso, Magdalena Sierra, Abelardo Bárez, José‐Ángel Hernández‐Rivas, Laura García Puente Suárez, Josefina Galende, María‐Victoria Mateos, Jesús F. San Miguel

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases

    Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases by Ramón García‐Sánz, Silvia Montoto, Agustín Torrequebrada, Alfonso García de Coca, J Petit, Anna Sureda, José Antonio Rodríguez‐García, Pilar Massó, Ana Pérez‐Aliaga, María Dolores Monteagudo, Isabel Navarro, Gemma Moreno, Carmen Toledo, Aránzazu Alonso, Carles Besses, Joan Besalduch, Isidro Jarque, Perla Salama, José‐Ángel Hernández‐Rivas, Blanca Navarro, Joan Bladé, Jesús F. San Miguel

    Published 2001
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  18. 18
    Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis

    Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis by Bruno Paiva, María‐Victoria Mateos, Luis Ignacio Sánchez‐Abarca, Noemí Puig, María‐Belén Vidriales, Lucía López‐Corral, Luís A. Corchete, Miguel‐Teodoro Hernández, Joan Bargay, Felipe de Arriba, Javier de la Rubia, Ana-Isabel Teruel, Pilar Giraldo, Laura Rosiñol, Felipe Prósper, Albert Oriol, José‐Ángel Hernández‐Rivas, Graça Esteves, Juan José Lahuerta, Joan Bladé, José Antonio Pérez‐Simón, Jesús F. San Miguel

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study

    Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study by Nuria Muñoz‐Rivas, Ane Abad‐Motos, B. Mestre-Gómez, Fernando Sierra‐Hidalgo, Cristina Cortina, Rosa M. Lorente‐Ramos, Pedro Torres Rubio, Paz Arranz-García, Anabel Franco‐Moreno, Eloy Gómez Mariscal, C. Mauleón-Fernández, Soledad Alonso-García, Jacobo Rogado, T. Sáez-Vaquero, A. Such-Díaz, Pablo Ryan, E. Moya-Mateo, Juan A. Martín-Navarro, José‐Ángel Hernández‐Rivas, Juan Torres‐Macho, Juan Churruca

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study

    Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study by Isabel Regalado‐Artamendi, Ana Jiménez Ubieto, José‐Ángel Hernández‐Rivas, Belén Navarro, Lucı́a Núñez, Concha Alaez, Raúl Córdoba, Francisco Javier Peñalver, Jimena Cannata, Pablo Estival, Keina Quiroz Cervantes, Rosalía Riaza Grau, Alberto Velasco, Rafael Martos, Amalia Domingo‐González, Laurentino Benito-Parra, Elvira Gómez-Sanz, Javier López‐Jiménez, Arturo Matilla, María Regina Herraez, María José Penalva, Julio García‐Suárez, José L. Díez‐Martín, Mariana Bastos‐Oreiro

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: